An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing a ...

While it has merit as a policy measure, it's the latest in a brutal series of administration actions that have hurt ...

Regeneron Chief Executive Leonard Schleifer said he welcomed the FDA ensuring that drugmakers don’t exaggerate their products ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 ®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to ...

Keratoconus has long been associated with atopic conditions like asthma, eczema and allergic conjunctivitis, and this ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to ...

The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints59% of patients ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...